vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $226.2M, roughly 1.2× USANA HEALTH SCIENCES INC). Astera Labs, Inc. runs the higher net margin — 16.6% vs 0.1%, a 16.5% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs -10.0%). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 3.1%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
ALAB vs USNA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $226.2M |
| Net Profit | $45.0M | $180.0K |
| Gross Margin | 75.6% | 78.2% |
| Operating Margin | 24.7% | 1.7% |
| Net Margin | 16.6% | 0.1% |
| Revenue YoY | 91.8% | -10.0% |
| Net Profit YoY | 82.0% | -74.0% |
| EPS (diluted) | $0.25 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $226.2M | ||
| Q3 25 | $230.6M | $213.7M | ||
| Q2 25 | $191.9M | $235.8M | ||
| Q1 25 | $159.4M | $249.5M | ||
| Q4 24 | $141.1M | $213.6M | ||
| Q3 24 | $113.1M | $200.2M | ||
| Q2 24 | $76.8M | $212.9M | ||
| Q1 24 | $65.3M | — |
| Q4 25 | $45.0M | $180.0K | ||
| Q3 25 | $91.1M | $-6.5M | ||
| Q2 25 | $51.2M | $9.7M | ||
| Q1 25 | $31.8M | $9.4M | ||
| Q4 24 | $24.7M | $4.5M | ||
| Q3 24 | $-7.6M | $10.6M | ||
| Q2 24 | $-7.5M | $10.4M | ||
| Q1 24 | $-93.0M | — |
| Q4 25 | 75.6% | 78.2% | ||
| Q3 25 | 76.2% | 77.2% | ||
| Q2 25 | 75.8% | 78.7% | ||
| Q1 25 | 74.9% | 79.0% | ||
| Q4 24 | 74.0% | 82.0% | ||
| Q3 24 | 77.7% | 80.4% | ||
| Q2 24 | 77.9% | 81.1% | ||
| Q1 24 | 77.4% | — |
| Q4 25 | 24.7% | 1.7% | ||
| Q3 25 | 24.0% | 0.6% | ||
| Q2 25 | 20.7% | 7.1% | ||
| Q1 25 | 7.1% | 6.3% | ||
| Q4 24 | 0.1% | 3.8% | ||
| Q3 24 | -7.9% | 7.8% | ||
| Q2 24 | -31.7% | 8.4% | ||
| Q1 24 | -127.1% | — |
| Q4 25 | 16.6% | 0.1% | ||
| Q3 25 | 39.5% | -3.1% | ||
| Q2 25 | 26.7% | 4.1% | ||
| Q1 25 | 20.0% | 3.8% | ||
| Q4 24 | 17.5% | 2.1% | ||
| Q3 24 | -6.7% | 5.3% | ||
| Q2 24 | -9.8% | 4.9% | ||
| Q1 24 | -142.5% | — |
| Q4 25 | $0.25 | $-0.10 | ||
| Q3 25 | $0.50 | $-0.36 | ||
| Q2 25 | $0.29 | $0.52 | ||
| Q1 25 | $0.18 | $0.49 | ||
| Q4 24 | $1.23 | $0.23 | ||
| Q3 24 | $-0.05 | $0.56 | ||
| Q2 24 | $-0.05 | $0.54 | ||
| Q1 24 | $-1.77 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $158.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | — |
| Total Assets | $1.5B | $742.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $158.4M | ||
| Q3 25 | $140.4M | $145.3M | ||
| Q2 25 | $162.3M | $151.3M | ||
| Q1 25 | $86.4M | $179.6M | ||
| Q4 24 | $79.6M | $181.8M | ||
| Q3 24 | $126.1M | $364.9M | ||
| Q2 24 | $421.1M | $332.4M | ||
| Q1 24 | $696.1M | — |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | $528.1M | ||
| Q2 25 | $1.1B | $531.1M | ||
| Q1 25 | $1.0B | $529.8M | ||
| Q4 24 | $964.8M | $532.1M | ||
| Q3 24 | $889.6M | $533.1M | ||
| Q2 24 | $845.3M | $512.2M | ||
| Q1 24 | $808.8M | — |
| Q4 25 | $1.5B | $742.9M | ||
| Q3 25 | $1.4B | $726.6M | ||
| Q2 25 | $1.3B | $734.5M | ||
| Q1 25 | $1.1B | $746.6M | ||
| Q4 24 | $1.1B | $748.2M | ||
| Q3 24 | $983.1M | $671.3M | ||
| Q2 24 | $915.5M | $631.4M | ||
| Q1 24 | $864.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | — |
| Free Cash FlowOCF − Capex | $76.6M | — |
| FCF MarginFCF / Revenue | 28.3% | — |
| Capex IntensityCapex / Revenue | 6.9% | — |
| Cash ConversionOCF / Net Profit | 2.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | — | ||
| Q3 25 | $78.2M | $-2.0M | ||
| Q2 25 | $135.4M | $12.2M | ||
| Q1 25 | $10.5M | $15.5M | ||
| Q4 24 | $39.7M | $5.8M | ||
| Q3 24 | $63.5M | $29.5M | ||
| Q2 24 | $29.8M | $8.0M | ||
| Q1 24 | $3.7M | — |
| Q4 25 | $76.6M | — | ||
| Q3 25 | $65.9M | $-5.2M | ||
| Q2 25 | $133.3M | $7.2M | ||
| Q1 25 | $6.0M | $12.7M | ||
| Q4 24 | $24.3M | $4.0M | ||
| Q3 24 | $46.8M | $27.1M | ||
| Q2 24 | $28.5M | $5.3M | ||
| Q1 24 | $228.0K | — |
| Q4 25 | 28.3% | — | ||
| Q3 25 | 28.6% | -2.4% | ||
| Q2 25 | 69.5% | 3.0% | ||
| Q1 25 | 3.7% | 5.1% | ||
| Q4 24 | 17.2% | 1.9% | ||
| Q3 24 | 41.4% | 13.6% | ||
| Q2 24 | 37.1% | 2.5% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 6.9% | — | ||
| Q3 25 | 5.3% | 1.5% | ||
| Q2 25 | 1.1% | 2.1% | ||
| Q1 25 | 2.8% | 1.1% | ||
| Q4 24 | 10.9% | 0.8% | ||
| Q3 24 | 14.8% | 1.2% | ||
| Q2 24 | 1.7% | 1.3% | ||
| Q1 24 | 5.2% | — |
| Q4 25 | 2.12× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 2.64× | 1.27× | ||
| Q1 25 | 0.33× | 1.65× | ||
| Q4 24 | 1.61× | 1.29× | ||
| Q3 24 | — | 2.78× | ||
| Q2 24 | — | 0.77× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
